What's in Centers for Disease Control and Prevention's pipeline?

Centers for Disease Control and Prevention has 61 drugs in our index: 35 marketed, 0 filed, 10 in Phase 3, 5 in Phase 2, 11 in Phase 1.

Which companies overlap with Centers for Disease Control and Prevention's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, University of Oxford, Sanofi, Sanofi Pasteur, a Sanofi Company, Merck Sharp & Dohme LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/centers-for-disease-control-and-prevention.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Centers for Disease Control and Prevention — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Centers for Disease Control and Prevention pipeline: 35 marketed, 0 filed, 10 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

35 marketed 0 filed 10 Phase 3 5 Phase 2 11 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
IPV at 6 weeks of age	IPV at 6 weeks of age	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3	Immunology / Infectious Disease
fIPV (0.2mL) IM	fIPV (0.2mL) IM	marketed	Inactivated viral vaccine		Immunology / Infectious Disease
mOPV2 at 6 and 10 weeks of age	mOPV2 at 6 and 10 weeks of age	marketed
IPV at 14 and 22 weeks of age, RotaTeq	IPV at 14 and 22 weeks of age, RotaTeq	marketed
REZ	REZ	marketed	Monoclonal antibody	CD19	Oncology
amodiaquine plus artesunate	amodiaquine plus artesunate	marketed
Artemether+Lumefantrine (AL)	Artemether+Lumefantrine (AL)	marketed	Artemisinin-based combination therapy (ACT)	Parasite heme metabolism; hemozoin formation	Infectious Disease
Anthrax Vaccine Adsorbed	Anthrax Vaccine Adsorbed	marketed
IPV at 14 and fIPV at 22 weeks, Rotarix	IPV at 14 and fIPV at 22 weeks, Rotarix	marketed
fIPV at 6-14-22 weeks of age, RotaTeq	fIPV at 6-14-22 weeks of age, RotaTeq	marketed
IPV at 6 and fIPV at 22 weeks, RotaTeq	IPV at 6 and fIPV at 22 weeks, RotaTeq	marketed
lumefantrine-artemether	lumefantrine-artemether	marketed	Antimalarial combination	Malaria parasite (Plasmodium) hemoglobin metabolism and mitochondrial function	Infectious Disease

Therapeutic area mix

Immunology / Infectious Disease · 13
Infectious Disease · 10
Immunology · 8
Infectious Diseases · 3
Other · 2
Infectious Disease / Virology · 2
Oncology · 1
Infectious Disease Diagnostics · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 9 shared drug classes
University of Oxford · 7 shared drug classes
Sanofi · 6 shared drug classes
Sanofi Pasteur, a Sanofi Company · 6 shared drug classes
Merck Sharp & Dohme LLC · 6 shared drug classes
Sinovac Biotech Co., Ltd · 5 shared drug classes
London School of Hygiene and Tropical Medicine · 5 shared drug classes
PATH · 4 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Centers for Disease Control and Prevention:

Cite this brief

Drug Landscape (2026). Centers for Disease Control and Prevention — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centers-for-disease-control-and-prevention. Accessed 2026-05-16.